Articles related to BIOLOGIC TREATMENTS

Combined omalizumab-OIT therapy demonstrated an impressive 50-percentage-point advantage over placebo in food challenge success rates for children with multiple food allergies.

Subcutaneous administration of amivantamab demonstrated noninferiority to IV delivery while potentially offering enhanced patient convenience and reduced healthcare system burden.

Understanding the role of antidrug antibodies in RA treatment can significantly impact patient management. Stay updated on how these antibodies correlate with bDMARD effectiveness to optimize your treatment plans.